Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

2 Jun 2023

Abstract excerpt

Mantle cell lymphoma (MCL) is an incurable B-cell malignancy with an overall poor prognosis, particularly for patients that progress on targeted therapies. Novel, more durable treatment options are needed for patients with MCL. Protein arginine methyltransferase 5 (PRMT5) is overexpressed in MCL and plays an important oncogenic role in this disease via epigenetic and posttranslational modification of cell cycle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to CAR-T cell therapy research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37267517
DOI: 10.1182/blood.2022019419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRMT5 supports multiple oncogenic pathways in mantle cell lymphomaPMID 37267517Read ↗

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.Semantic proximity Read ↗

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.Semantic proximity Read ↗

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformationSemantic proximity Read ↗

Clinical-Preclinical Connections Solidified the Foundation Supporting PRMT5 as a Reliable Lymphoma Prognosis BiomarkerSemantic proximity Read ↗

Targeting CDK4/6 in mantle cell lymphomaSemantic proximity Read ↗

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSemantic proximity Read ↗

LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2Semantic proximity Read ↗

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.Semantic proximity Read ↗

Biological and clinical determinants shaping heterogeneity in mantle cell lymphomaSemantic proximity Read ↗

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.Semantic proximity Read ↗

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraSemantic proximity Read ↗

Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.